Entrada Therapeutics Inc (TRDA) — Capital Reinvestment Ratio

Latest as of June 2024: 0.03x

Entrada Therapeutics Inc (TRDA) has a Capital Reinvestment Ratio of 0.03x as of June 2024, meaning it reinvests 0% of its operating cash flow ($39.83 Million) in capital expenditures ($1.05 Million). See TRDA equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$39.83 Million
USD

Capital Expenditures

$1.05 Million
USD

Data as of

Jun 2024
Most recent filing

Entrada Therapeutics Inc Capital Reinvestment Ratio (2023–2023)

This chart tracks Entrada Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check cash flow reinvestment rate of Entrada Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Entrada Therapeutics Inc (2023–2023)

Year-by-year Capital Reinvestment Ratio for Entrada Therapeutics Inc from 2023 to 2023. For live market cap and broader valuation context, see how much is Entrada Therapeutics Inc worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.04x $139.80 Million $5.61 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow